Lineage Cell Therapeutics Expands Pipeline with NeuroAirmid Acquisition and Projects Cash Runway to Q2 2028
Lineage Cell Therapeutics (LCTX) has announced a strategic expansion of its clinical pipeline through the acquisition of NeuroAirmid Therapeutics. This transformational deal introduces the HUNT1 Phase Ib/IIa program, targeting Huntington’s disease, which marks the company's third clinical-stage cell therapy program. During the Q3 2026 earnings call, CEO Brian Culley highlighted the importance of this acquisition in diversifying the company's therapeutic offerings. Furthermore, management provided updated financial guidance, projecting a cash runway that extends into the second quarter of 2028, providing stability for ongoing clinical developments.
Topics: acquisition cell therapy clinical stage programs earnings call